Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of GTX-101 vs Subcutaneous Bupivacaine in Healthy Subjects
NCT05517486Phase 1Unknown
- Sponsor
- Grace Therapeutics, Inc.
- Start
- Jul 2022
- Primary completion
- Aug 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GTX-101 in postherpetic neuralgia (PHN) (4 arms), sponsored by Grace Therapeutics, Inc. Primary endpoints: Maximum Plasma Concentration (Cmax), Time to Maximum Plasma Concentration (Tmax) and 2 more. Status: unknown.
02
Drugs
GTX-101
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT05517486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05517486.